Regulus Therapeutics Analyst Ratings
Regulus Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/21/2023 | 587.02% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 09/19/2023 | 587.02% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 08/10/2023 | 587.02% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 06/28/2023 | 587.02% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 06/21/2023 | 587.02% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 05/15/2023 | 587.02% | HC Wainwright & Co. | → $9 | Reiterates | Buy → Buy |
| 04/21/2023 | 587.02% | HC Wainwright & Co. | $20 → $9 | Maintains | Buy |
| 11/08/2022 | 587.02% | Canaccord Genuity | → $9 | Initiates Coverage On | → Buy |
| 09/02/2021 | 52.67% | Cantor Fitzgerald | → $2 | Initiates Coverage On | → Overweight |
| 05/14/2021 | 52.67% | HC Wainwright & Co. | $1.5 → $2 | Maintains | Buy |
| 05/04/2020 | 14.5% | HC Wainwright & Co. | $2 → $1.5 | Reiterates | → Buy |
| 09/06/2019 | 52.67% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
| 03/19/2019 | 14.5% | Wells Fargo | $6 → $1.5 | Maintains | Market Perform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年09月21日 | 587.02% | HC Wainwright公司 | →$9 | 重申 | 購買→購買 |
| 2023/09/19 | 587.02% | HC Wainwright公司 | →$9 | 重申 | 購買→購買 |
| 2023年08月10日 | 587.02% | HC Wainwright公司 | →$9 | 重申 | 購買→購買 |
| 2023年6月28日 | 587.02% | HC Wainwright公司 | →$9 | 重申 | 購買→購買 |
| 2023年6月21日 | 587.02% | HC Wainwright公司 | →$9 | 重申 | 購買→購買 |
| 2023年05月15日 | 587.02% | HC Wainwright公司 | →$9 | 重申 | 購買→購買 |
| 04/21/2023 | 587.02% | HC Wainwright公司 | $20→$9 | 維護 | 買 |
| 11/08/2022 | 587.02% | 卡納科特·格納奇 | →$9 | 開始承保 | →購買 |
| 09/02/2021 | 52.67% | 康託·菲茨傑拉德 | →$2 | 開始承保 | →超重 |
| 2021/05/14 | 52.67% | HC Wainwright公司 | $1.5→$2 | 維護 | 買 |
| 05/04/2020 | 14.5% | HC Wainwright公司 | $2→$1.5 | 重申 | →購買 |
| 2019年06月09日 | 52.67% | HC Wainwright公司 | →$2 | 開始承保 | →購買 |
| 2019/03/19 | 14.5% | 富國銀行 | $6→$1.5 | 維護 | 市場表現 |
What is the target price for Regulus Therapeutics (RGLS)?
Regulus Treeutics(RGLS)的目標價格是多少？
The latest price target for Regulus Therapeutics (NASDAQ: RGLS) was reported by HC Wainwright & Co. on September 21, 2023. The analyst firm set a price target for $9.00 expecting RGLS to rise to within 12 months (a possible 587.02% upside). 8 analyst firms have reported ratings in the last year.
HC Wainwright&Co.於2023年9月21日報道了Regulus治療公司(納斯達克：RGLS)的最新目標價。這家分析公司將目標價定為9美元，預計RGLS將在12個月內升至(可能上漲587.02%)。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for Regulus Therapeutics (RGLS)?
Regulus Treeutics(RGLS)的最新分析師評級是多少？
The latest analyst rating for Regulus Therapeutics (NASDAQ: RGLS) was provided by HC Wainwright & Co., and Regulus Therapeutics reiterated their buy rating.
對Regulus治療公司(納斯達克代碼：RGLS)的最新分析師評級由HC Wainwright&Co.提供，Regulus治療公司重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Regulus Therapeutics (RGLS)?
Regulus治療公司(RGLS)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regulus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regulus Therapeutics was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Regulus Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Regulus治療公司的最後一次評級是在2023年9月21日提交的，所以你應該預計下一次評級將在2024年9月21日左右的某個時候提供。
Is the Analyst Rating Regulus Therapeutics (RGLS) correct?
分析師評級Regulus Treeutics(RGLS)正確嗎？
While ratings are subjective and will change, the latest Regulus Therapeutics (RGLS) rating was a reiterated with a price target of $0.00 to $9.00. The current price Regulus Therapeutics (RGLS) is trading at is $1.31, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Regulus治療公司(RGLS)的評級被重申，目標價在0.00美元到9.00美元之間。Regulus治療公司(RGLS)目前的交易價格為1.31美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。